Published online 2015 August 24.

Letter

# Oral Therapy in a Diabetic Patient With History of Infantile Hyperinsulinism

Hossein Moravej<sup>1</sup>; Zohreh Karamizadeh<sup>1,\*</sup>; Omid Aryani<sup>2</sup>

<sup>1</sup>Department of Pediatrics, Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran

<sup>2</sup>Medical Genetics Department, Special Medical Center, Tehran, IR Iran

\*Corresponding author: Zohreh Karamizadeh, Department of Pediatrics, Medical School, Shiraz University of Medical Sciences, Shiraz, IR Iran. Tel/Fax: +98-7116474298, E-mail: zkaramizadeh@yahoo.com

Received: December 25, 2013; Revised: May 14, 2014; Accepted: July 26, 2014

Keywords: Patient; Mutation; Hyperinsulinism

# Dear editor,

Hyperinsulinism is the most common cause of persistent hypoglycemia in early infancy (1). Loss of function mutation in HNF4A gene is an unusual cause of this disease (2). HNF4A protein is a homodimer nuclear transcription factor with 474 amino acids which plays a role in 22 identified pathways. Mutations in this gene cause deficiency in regulation of beta-cell development and nuclear receptors transcription pathways, associated with maturity onset diabetes of Young (MODY) and HNF4Arelated hyperinsulinism (3, 4).

Association of hyperinsulinemia in infancy and diabetes in adolescence has been reported only in patients with HNF4A mutations (4).

We present a patient with hyperinsulinmia in infancy and diabetes in adolescence without HNF4A mutation and with good response to oral hypoglycemic agents.

In infancy, this patient presented with persistent hyperinsulinemic hypoglycemia. He was on oral diazoxide until 3 years of age when this drug was tapered and discontinued. Genetic study was not performed at that time due to limitation of facilities. After that time, his blood sugar was normal until 15 years of age when he presented with diabetes mellitus. Starting HbA1c was 9.5%.

In addition, fasting triglyceride level and cholesterol level was 66 mg/dL and 168 mg/dL, respectively. Other routine laboratory studies were within the normal range. Pancreas anatomy was also normal in ultrasonography.

At the time of manifestation of diabetes, he was 162 cm tall (about 25th percentile for sex and age) and 51 kg (about 25th percentile for sex and age). He did not have any family history of diabetes.

Insulin therapy associated with oral sylfonylurea (Glibenclamid) was started with impression of monogenic diabetes. As he responded, insulin dose was gradually tapered and discontinued, and an  $\alpha$ -glucodisase inhibitor (Acarbose) was started to improve his mild postpran-

dial hyperglycemia. The treatment was continued with 0.1 mg/kg/day Glibenclamid and 50 mg Acarbose before each meal. Self-monitoring of blood glucose by the patient and most of the measurements were in the target range (70-130 mg/dL). After 4 months of treatment, HbA1c was 6.7%. He tolerated the medications well without any side effect.

According to previous history of the patient, the most probable diagnosis was HNF40 mutation. However, the results of HNF40 gene study by DNA sequencing method revealed no mutation and only a previously reported variant rs745975 C > T determined in nucleotide 5 of intron 1 (5). This variant was associated with Stearoyl-CoA desaturase 1 activity (6) and with type 2 diabetes mellitus (7).

History of hyperinsulinism in infancy, diabetes mellitus in adolescence, low plasma triglyceride level, and good response to oral hypoglycemic agents has been reported in previous cases of MODY type 1 with HNF4A mutation (8). Mutation in HNF4A was not found in the presented case and due to shortage of facilities, more genetic study was not performed, however, his clinical course is in favor of a type of monogenic diabetes. This case showed that some adolescent diabetic patients, even without family history of diabetes, and without clinical characteristics of type 2 diabetes may have good response to oral hypoglycemic agents. Further studies are needed to find more cases of monogenic diabetes in adolescents, and to determine which diabetic adolescent can be treated with oral agents. Also, it is recommended that in every patient whose diabetes commences in adolescence, a precise history about hypoglycemia of infancy should be obtained.

#### Acknowledgements

Research Improvement Center of Shiraz University of

Copyright @ 2015, Growth & Development Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Medical Sciences, Shiraz, Iran and Ms. A. Keivanshekouh are appreciated for improving the use of English in the manuscript.

### **Authors' Contributions**

Hossein Moravej and Zohreh Karamizadeh contributed substantially to conception and design, acquisition of data, analysis and interpretation of data AND drafted the article. Omid Aryani contributed to laboratory analysis.

## References

- De Leon DD, Stanley CA. Mechanisms of Disease: advances in diagnosis and treatment of hyperinsulinism in neonates. Nat Clin Pract Endocrinol Metab. 2007;3(1):57–68.
- Palladino AA, Bennett MJ, Stanley CA. Hyperinsulinism in infancy and childhood: when an insulin level is not always enough. *Clin Chem.* 2008;54(2):256–63.

- Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, et al. Control of pancreas and liver gene expression by HNF transcription factors. *Science*. 2004;**303**(5662):1378–81.
- Flanagan SE, Kapoor RR, Hussain K. Genetics of congenital hyperinsulinemic hypoglycemia. Semin Pediatr Surg. 2011;20(1):13–7.
- Zhang R, Hu C, Wang CR, Fang QC, Ma XJ, Jia WP, et al. [Scanning the HNF4A gene mutation from Chinese pedigrees with early- and/ or multiple-onset diabetes]. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. 2006;23(4):406–9.
- Mar-Heyming R, Miyazaki M, Weissglas-Volkov D, Kolaitis NA, Sadaat N, Plaisier C, et al. Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2008;28(6):1193–9.
- Barroso I, Luan J, Wheeler E, Whittaker P, Wasson J, Zeggini E, et al. Population-specific risk of type 2 diabetes conferred by HNF4A P2 promoter variants: a lesson for replication studies. *Diabetes*. 2008;**57**(11):3161–5.
- Schober E, Rami B, Grabert M, Thon A, Kapellen T, Reinehr T, et al. Phenotypical aspects of maturity-onset diabetes of the young (MODY diabetes) in comparison with Type 2 diabetes mellitus (T2DM) in children and adolescents: experience from a large multicentre database. *Diabet Med.* 2009;26(5):466-73.